2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical‐scale in vitro expansion preserves biological characteristics of cardiac atrial appendage stem cells

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          Cardiac atrial appendage stem cells ( CASCs) have recently emerged as an attractive candidate for cardiac regeneration after myocardial infarction. As with other cardiac stem cells, CASCs have to be expanded ex vivo to obtain clinically relevant cell numbers. However, foetal calf serum ( FCS), which is routinely used for cell culturing, is unsuitable for clinical purposes, and influence of long‐term in vitro culture on CASC behaviour is unknown.

          Materials and methods

          We examined effects on CASC biology of prolonged expansion, and evaluated a culture protocol suitable for human use.

          Results

          In FCS‐supplemented medium, CASCs could be kept in culture for 55.75 ± 3.63 days, before reaching senescence. Despite a small reduction in numbers of proliferating CASCs (1.37 ± 0.52% per passage) and signs of progressive telomere shortening (0.04 ± 0.02 kb per passage), their immunophenotype and myocardial differentiation potential remained unaffected during the entire culture period. The cells were successfully expanded in human platelet plasma supernatant, while maintaining their biological properties.

          Conclusions

          We successfully developed a protocol for long‐term culture, to obtain clinically relevant CASC numbers, while retaining their cardiogenic potential. These insights in CASC biology and optimization of a humanized platelet‐based culture method are an important step towards clinical application of CASCs for cardiac regenerative medicine.

          Related collections

          Author and article information

          Journal
          Cell Prolif
          Cell Prolif
          10.1111/(ISSN)1365-2184
          CPR
          Cell Proliferation
          John Wiley and Sons Inc. (Hoboken )
          0960-7722
          1365-2184
          29 January 2015
          April 2015
          : 48
          : 2 ( doiID: 10.1111/cpr.2015.48.issue-2 )
          : 175-186
          Affiliations
          [ 1 ] Laboratory of Experimental Hematology Jessa Hospital 3500 Hasselt Belgium
          [ 2 ] Faculty of Medicine and Life Sciences Hasselt University 3590 Diepenbeek Belgium
          [ 3 ] University Biobank Limburg Jessa Hospital 3500 Hasselt Belgium
          [ 4 ] Department of Cardiothoracic Surgery Jessa Hospital 3500 Hasselt Belgium
          Author notes
          [*] [* ]Correspondence: K. Hensen, Laboratory of Experimental Hematology, Jessa Hospital, Campus Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium. Tel.: (+32) (0)11338266; Fax: (+32) (0)11338208; E‐mail: karen.hensen@ 123456jessazh.be
          [†]

          These authors contributed equally to this work.

          Article
          PMC6495491 PMC6495491 6495491 CPR12166
          10.1111/cpr.12166
          6495491
          25630660
          2b5aa1a8-8140-49fd-91e4-9094f6eafeba
          © 2015 John Wiley & Sons Ltd
          History
          : 05 September 2014
          : 14 October 2014
          Page count
          Pages: 12
          Funding
          Funded by: Agency for Innovation by Science and Technology in Flanders
          Funded by: Limburg Sterk Merk
          Categories
          Original Article
          Original Articles
          Custom metadata
          2.0
          cpr12166
          April 2015
          Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.2.1 mode:remove_FC converted:02.05.2019

          Comments

          Comment on this article